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Abstract
The dose-dependent effects of 5,6-dimethylxanthe-
none-4-acetic acid (DMXAA) on rat GH3 prolactinomas
were investigated in vivo. Dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) was used to
assess tumor blood flow/permeability pretreatment
and 24 hours posttreatment with 0, 100, 200, or
350 mg/kg DMXAA. DCE-MRI data were analyzed using
K trans and the integrated area under the gadolinium
time curve (IAUGC) as response biomarkers. High-
performance liquid chromatography (HPLC) was used
to determine the plasma concentration of the seroto-
nin metabolite 5-hydroxyindoleacetic acid (5-HIAA)
following treatment to provide an index of increased
vessel permeability and vascular damage. Finally, tumor
necrosis was assessed by grading hematoxylin and
eosin–stained sections cut from the same tumors inves-
tigated by MRI. Both tumor K trans and IAUGC were sig-
nificantly reduced24hoursposttreatmentwith350mg/kg
DMXAA only, with no evidence of dose response. HPLC
demonstrated a significant increase in plasma 5-HIAA
24 hours posttreatment with 200 and 350 mg/kg DMXAA.
Histologic analysis revealed some evidence of tumor
necrosis following treatment with 100 or 200 mg/kg
DMXAA, reaching significance with 350 mg/kg DMXAA.
The absence of any reduction in K trans or IAUGC
following treatment with 200 mg/kg, despite a significant
increase in 5-HIAA, raises concerns about the utility of
established DCE-MRI biomarkers to assess tumor re-
sponse to DMXAA.
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Introduction
The network of tumor blood vessels that perfuse a solid
tumor plays a fundamental role in its growth and survival.
Not only do the blood vessels feed the tumor with oxygen
and nutrients through the blood, they also allow for the
subsequent removal of cellular waste products. Vascular-
disrupting agents (VDAs) are a class of cancer therapeutics
that cause a rapid and selective shutdown of established tumor
blood vessels. Subsequently, the blood supply that feeds the
tumor is diminished, and the tumor tissue becomes necrotic
due to prolonged ischemia [1,2]. It is hypothesized that VDAs
cause a selective shutdown of tumor blood flow by targeting
and destroying the endothelial cells of tumor blood vessels [2].
The selectivity of VDAs for the tumor vasculature is thought to
be due to the exaggerated proliferation rate of tumor blood
vessel endothelial cells, which is much more rapid than that
of normal quiescent endothelial cells [3].
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a low-
molecular-weight VDA that has completed phase I single-agent
trials and is now in phase II trials, in combination with chemo-
therapy, for the treatment of various cancers [2]. There is often
no visible tumor shrinkage in response to DMXAA or other VDA
treatment, but tumor growth after treatment may be delayed.
This is because VDAs typically induce central necrosis but
leave a viable rim of cells at the periphery of the tumor, which
eventually causes tumor cell repopulation [1,2]. Due to the na-
ture of its antitumor action, the clinical development of DMXAA
requires biomarkers associated with its vascular-disrupting
activity. Dynamic contrast-enhanced magnetic resonance im-
aging (DCE-MRI) is a noninvasive technique commonly used
in both preclinical and clinical oncology to assess the action
of anticancer therapies in vivo. DCE-MRI reveals the kinetics
of intravenously administered contrast agent ‘‘wash-in’’ and
‘‘wash-out’’ to give information on tumor perfusion and blood
vessel permeability. The two recommended primary DCE-
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MRI–derived biomarkers for the assessment of antivascular
therapeutics are K trans (min1) and the integrated area under
the gadolinium time curve (IAUGC) (mM Gd min) [4]. Be-
cause DCE-MRI can provide physiological information that is
directly related to the tumor vasculature, it is an ideal method
for monitoring the effectiveness of DMXAA and other VDAs
as they target tumor blood vessels [4].
In addition to using DCE-MRI, the antivascular effects
of DMXAA were also monitored by measuring the change
in the plasma concentration of the serotonin metabolite
5-hydroxyindoleacetic acid (5-HIAA) following treatment.
The rationale for using plasma 5-HIAA levels as a surrogate
marker of antivascular effects arises from preclinical studies
in mice in which the release of serotonin into the plasma
appears to be a feature associated with the antivascular
action of DMXAA [5]. It is most likely that this occurs as a
consequence of an accumulation of aggregated platelets at
the sites of vascular damage, releasing the vasoactive amine
serotonin. Measurements of plasma 5-HIAA concentration
have also been used in phase I clinical trials of DMXAA to
monitor its antitumor activity in patients [6].
The aim of this study was to further investigate the dose
response of tumors to DMXAA using DCE-MRI and the
quantitation of 5-HIAA levels after treatment in a rat tumor
model. A rat model was chosen because rats, like humans,
can tolerate far greater doses of DMXAA than mice, which
appear to be very sensitive to the drug [7,8]. DCE-MRI data
were analyzed using K trans and IAUGC as response bio-
markers to changes in tumor blood flow and permeability
following treatment [4]. A 24-hour posttreatment time point
was used for all doses in the study. An additional cohort
of tumor-bearing rats was investigated prior to treatment
(pretreatment) and 4 hours posttreatment with 200 mg/kg
DMXAA. This decision was in support of the current phase II
clinical trials in which patients are administered 1200 mg/m2
DMXAA (a dose approximately equating to 200 mg/kg in
rats) [9] and any antivascular effect is evaluated 4 hours
posttreatment. In addition, the degree of tumor necrosis
induced by DMXAA was also assessed by grading hema-
toxylin and eosin–stained sections cut from the same tumors
used in the study.
Materials and Methods
Cell Culture
GH3 rat prolactinoma cells were maintained in Ham’s F10
media (Sigma, Poole, Dorset, UK) supplemented with 15%
fetal calf serum (Life Technologies, Grand Island, NY) and 1%
penicillin–streptomycin (Life Technologies). The cells were
incubated at 37jC in a humidified atmosphere of 5% CO2
and 95% air. When confluent, the cells were harvested using
trypsin–EDTA (Life Technologies) and then resuspended
in media.
Animals and Tumors
Female Wistar Furth rats weighing ca. 160 g were anes-
thesized under halothane, and the fur covering the right
flank was shaved. A total of 1  107 GH3 cells were then
injected subcutaneously using a 25-gauge needle. Tumors
were propagated from cells in culture in the first instance,
and subsequent tumors were propagated by serial pas-
sage up to the fifth passage. When the fifth passage had
been reached, the tumors were reinitiated from cells in cul-
ture and the cycle was repeated as before. To carry out the
passage from animal to animal, a tumor was excised from a
tumor-bearing rat under anesthesia and transferred to a
sterile beaker. It was then minced into a homogenate using
sterile scissors and media. The homogenate was then fil-
tered through gauze, and the cells were harvested by cen-
trifugation. The cells were then resuspended in media prior
to injection into animals. Tumor weight was measured using
calipers, assuming an ellipsoid shape and using the for-
mula: l  w  d(p / 6). Tumors were subsequently used for
DCE-MRI when they reached a weight of ca. 6000 mg.
Administration of DMXAA
DMXAA was formulated in sterile water (200 mg/ml) and
administered to rats by a single intraperitoneal injection.
DCE-MRI data were acquired pretreatment and either
4 hours posttreatment with 200 mg/kg DMXAA (n = 7) or
24 hours posttreatment with 0 mg/kg (n = 6), 100 mg/kg
(n = 7), 200 mg/kg (n = 8), or 350 mg/kg (n = 7) DMXAA.
Tumor Growth Curve
A separate cohort of tumors was propagated, and their
growth was measured for 5 days after the administration of
vehicle (n = 4) or 350 mg/kg DMXAA (n = 4) to assess tumor
growth delay.
Preparation of Contrast Agent
Gadodiamide (Omniscan; GE Healthcare, Bucks, UK)
contrast agent solution (500 mM) was diluted with ster-
ile water (18:100) and administered to rats at a dose of
0.1 mmol/kg.
DCE-MRI
Anesthesia was induced by an intraperitoneal injection
(4 mg/ml) of a combination of fentanyl citrate (0.315 mg/ml),
fluanisone (10 mg/ml) (Hypnorm; Janssen Pharmaceutical,
Oxford, UK), and midazolam (5 mg/ml) (Roche, Welwyn
Garden City, Herts, UK). The rat was then positioned on a
platform so that the tumor hung down into a three-turn so-
lenoid coil to acquire tumor data, and the tail was fed through
a nine-turn solenoid coil to acquire arterial input function
(AIF) data from large tail vessels [10]. A lateral tail vein
was cannulated for the administration of Omniscan using a
27-gauge butterfly catheter (Venisystems; Abbott Labora-
tories, Sligo, Ireland) attached to a tubing with a 1-ml syringe
at the end. The syringe was then placed in a programmable
power injector (Harvard PHD 2000, Harvard Apparatus, Hol-
liston, MA), which was triggered by the spectrometer. A
plastic blanket with warm circulating water was used to main-
tain the rat core temperature at 37jC while inside the magnet.
MRI was performed on a 4.7-T horizontal bore magnet
(Oxford Instruments, Abington, Oxfordshire, UK) interfaced
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with a Varian Unity Inova spectrometer (Varian NMR In-
struments, Palo Alto, CA). Baseline tumor T1 data were
acquired using an inversion-recovery fast low-angle shot
(IR-FLASH) sequence with an adiabatic inversion pulse.
Flip-angle maps were acquired from three contiguous trans-
verse 2-mm slices using the IR-FLASH sequence and a
series of T1-weighted gradient-echo sequences with different
repetition times [11]. The flip-angle maps were acquired to
correct for the nonuniformity of the B1 field of the tumor coil.
For the DCE-MRI experiment, spin-echo images of the
tail were acquired to remove R2* effects and to provide an
AIF, and while a gradient-echo sequence was used for
the tumor. The coils were switched electronically using the
spectrometer for interleaved acquisition of tumor and tail
images. The images were 64  64 points. The repetition
time (TR) was 120 milliseconds and the echo time (TE) was
3 milliseconds for gradient-echo tumor images, resulting in a
time resolution of 7.68 seconds for the DCE-MRI sequence.
Thirty-two scans were acquired prior to the injection of
Omniscan, and 180 scans were acquired after the injection
of 0.1 mmol/kg Omniscan.
DCE-MRI Data Analysis
Data were analyzed using MATLAB 6.5. First, an experi-
mental flip-angle map of each tumor slice was calculated
from the baseline T1 map and the gradient-echo series. A
simulated flip-angle map was then fitted to this experimen-
tal map using a three-dimensional model of the coil and the
Biot-Savart law. Although an AIF was acquired from each
rat in the study, this was used solely for quality control and
acceptance of the data. A previously measured generic
AIF was used for data analysis [10]. For the analysis of
MRI data, a theoretical pharmacokinetic model was ap-
plied to the T1 tumor maps and gadolinium data. The method
of Tofts and Kermode [12] was used for the determination
of K trans. The IAUGC method was also applied to the data,
integrating over the first 60 seconds [13]. K trans and IAUGC
histograms were generated using the data pooled from all
three tumor slices, and the median K trans and IAUGC values
were determined from the whole tumor.
High-Performance Liquid Chromatography (HPLC)
Sample Collection
Following the posttreatment scan, laparotomy was per-
formed, and blood was taken from the aorta of the rat and
transferred to a heparinized tube. Plasma was separated
from the blood by centrifugation (10,000g, 10 minutes, 4jC)
and transferred to a cryotube for storage in liquid nitrogen
until analysis. Sample preparation and HPLC assay for
plasma 5-HIAA were performed according to the method
described by Kestell et al. [14].
Histology
Once blood samples had been taken for HPLC, the
animals were sacrificed, and the tumors were excised and
fixed in formal saline. Owing to their large size, the tumor
was then dissected into three or four slices before being em-
bedded in paraffin, cut, and stained with Ehrlich’s hema-
toxylin and eosin. Histologic sections were analyzed using
a qualitative scoring system with the following categories:
grade 1, no necrosis; grade 2, patchy necrosis; grade 3, cen-
tral necrosis; grade 4, extensive necrosis. Statistical analysis
was performed using Mann-Whitney U test.
Results
Figure 1 shows an example of K trans maps of a tumor
pretreatment and 24 hours posttreatment with 350 mg/kg
DMXAA. On visual inspection, the control tumors and those
treated with 100 mg/kg DMXAA showed little or no change in
contrast agent uptake 24 hours posttreatment, whereas the
tumors treated with 200 or 350 mg/kg DMXAA typically
showed a decrease in contrast agent uptake, mainly asso-
ciated with the tumor core, 4 and 24 hours posttreatment.
Examples of IAUGC and K trans histograms of a tumor
pretreatment and 24 hours posttreatment with vehicle or
350 mg/kg DMXAA are shown in Figures 2 and 3. Overall,
there was little or no change in the posttreatment IAUGC
and K trans histograms for the control tumors or for the tu-
mors treated with 100 mg/kg DMXAA. Generally, a shift to
the left was seen in the posttreatment histograms, indicating
a reduction in IAUGC and K trans for the tumors treated with
200 or 350 mg/kg DMXAA.
Pretreatment and posttreatment K trans values derived
from tumors of individual rats are shown in Figure 4. There
was no consistent response seen at lower doses, but at the
highest dose of 350 mg/kg DMXAA, six tumors showed a
decrease and one tumor showed an increase in K trans. Mean
K trans and IAUGC data for each cohort of rats are presented
in Table 1 and Figure 5. There was a significant 21% re-
duction in IAUGC and a significant 26% reduction in K trans
24 hours posttreatment with 350 mg/kg DMXAA (P < .05,
Student’s paired t test).
Mean plasma 5-HIAA concentrations in rats for each
treatment cohort are summarized in Figure 6. No significant
changes were observed between basal plasma 5-HIAA
concentrations within the control cohort and those measured
in rats either 24 hours posttreatment with 100 mg/kg DMXAA
or 4 hours posttreatment with 200 mg/kg DMXAA. However,
rat plasma 5-HIAA concentrations were significantly ele-
vated (P < .05, Student’s t test) 24 hours posttreatment with
DMXAA at doses of either 200 or 350 mg/kg.
Figure 1. K trans maps from a single slice through a GH3 prolactinoma (A)
pretreatment and (B) 24 hours posttreatment with 350 mg/kg DMXAA.
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Examples of hematoxylin and eosin–stained sections of
rat tumors 24 hours posttreatment with vehicle or 350 mg/kg
DMXAA are shown in Figure 7. The necrotic tissue is pale,
and the viable tissue is dark pink. The median necrosis grade
induced by DMXAA treatment is shown in Figure 8. The
control tumors and the tumors treated with 200 mg/kg
DMXAA for 4 hours were mostly scored as grade 1, which
indicates no necrosis. Most tumors treated with 100 or
200 mg/kg DMXAA for 24 hours were given a score of
grade 2, which indicates patchy necrosis. The tumors treated
with 350 mg/kg DMXAA were given either a score of grade 3
(which indicates central necrosis) or a score of grade 4
(which indicates extensive necrosis). The necrosis induced
by the 350 mg/kg DMXAA treatment cohort was statistically
significant in comparison to controls (P < .05, Mann-Whitney
U test).
A single dose of 350 mg/kg DMXAA, compared to vehicle,
induced a significant growth delay of GH3 prolactinomas
(Figure 9).
Discussion
The aim of this study was to investigate the effects of
DMXAA on the tumor vasculature and to determine at what
doses these antivascular effects occur in a rat tumor model.
To perform the study, DCE-MRI was used to assess the
changes in tumor blood flow and permeability, and HPLC
was used to measure the serotonin metabolite 5-HIAA in
plasma (a surrogate marker of vascular damage and in-
creased vessel permeability). In addition, hematoxylin and
eosin staining was used to assess tumor necrosis.
The antivascular action of DMXAA on rat tumors was
assessed by the derivation of K trans and IAUGC values. It is
hypothesized that VDAs should cause a reduction in K trans
and IAUGC because they induce vascular collapse and re-
duce tumor blood flow. Indeed, these have been the find-
ings of preclinical and clinical DCE-MRI studies of other
VDAs, such as combretastatin and ZD6126 [15–17]. In par-
ticular, a dose-dependent reduction in IAUGC 24 hours post-
treatment with ZD6126 was measured in the same rat GH3
prolactinoma tumor model used in this study [16]. It is ap-
parent from the results of this study that DMXAA can cause
both a decrease and an increase in K trans and IAUGC. These
findings are particularly highlighted by the pretreatment and
posttreatment K trans measurements for individual tumors
in Figure 4. Previous clinical studies of DMXAA have also
shown significant increases in K trans at 2400mg/m2 (approxi-
mately 399 mg/kg in rats), as well as significant reductions
in IAUGC between 650 and 1200 mg/m2 (approximately 108
and 200 mg/kg, respectively, in rats) (M. McKeage, personal
communication) [18,19].
The inconsistent response in K trans and IAUGC seen fol-
lowing treatment may be explained by the proposed mecha-
nism of action of DMXAA, which, despite culminating in the
same overall antitumor effect as other VDAs (i.e., induction
of tumor necrosis through blood vessel disruption), is ac-
tually very different.
Figure 3. (A) IAUGC and (B) K trans histograms of a GH3 prolactinoma
pretreatment and 24 hours posttreatment with 350 mg/kg DMXAA.
Figure 2. (A) IAUGC and (B) K trans histograms of a GH3 prolactinoma tumor
model pretreatment and 24 hours posttreatment with vehicle only.
202 Antivascular and Antitumor Effects of DMXAA McPhail et al.
Neoplasia . Vol. 8, No. 3, 2006
Most lead VDAs are tubulin-binding agents, which work
by targeting the tubulin cytoskeleton of proliferating endo-
thelial cells lining tumor blood vessels, subsequently chang-
ing their morphology and inhibiting proliferation. DMXAA is
an unusual VDA because it does not work through tubulin
binding, but instead stimulates the induction of cytokines,
which have both antivascular and antitumor effects [20]. To
date, the most extensively studied cytokine induced by
DMXAA is tumor necrosis factor-a (TNF-a). Several studies
have shown that cytokines, TNF-a in particular, can increase
vascular permeability [21–25]. TNF-a can also decrease
tumor blood flow by inducing vascular collapse and hemor-
rhage [26,27]. In addition to cytokine induction, it has been
demonstrated that DMXAA can cause direct vascular dam-
age through the induction of endothelial cell apoptosis—
another effect that could increase vessel permeability [28].
Changes in K trans and IAUGC are related to changes in
both tumor blood flow and vessel permeability; the two
physiological parameters cannot be decoupled [4]. Taking
into consideration that DMXAA promotes cytokine induction
and endothelial cell apoptosis (two effects that can both in-
crease vessel permeability and decrease tumor blood flow),
it may be that there is a significant effect induced by in-
termediate doses of DMXAA but this could be undetected
by DCE-MRI, as the effects of increased permeability and
Figure 4. Line series graphs showing K trans values for individual rats (A) pretreatment and 24 hours posttreatment with 100 mg/kg DMXAA; (B) pretreatment and
4 hours posttreatment with 200 mg/kg DMXAA; (C) pretreatment and 24 hours posttreatment with 200 mg/kg DMXAA; and (D) pretreatment and 24 hours
posttreatment with 350 mg/mg DMXAA.
Table 1. Summary of K trans and IAUGC Values Pretreatment and 4 Hours
Posttreatment with 200 mg/kg DMXAA and 24 Hours Posttreatment with 0,
100, 200, or 350 mg/kg DMXAA.
DMXAA Mean K trans (103 s1) Mean IAUGC (mM Gd min)
Dose (mg/kg)
Pretreatment Posttreatment Pretreatment Posttreatment
Control 2.30 ± 0.3 2.17 ± 0.4 14.6 ± 1.1 13.9 ± 1.0
100 (24 h, n=6) 1.71 ± 0.2 1.98 ± 0.3 12.0 ± 0.7 13.2 ± 1.3
200 (4 h, n=7) 1.60 ± 0.1 1.63 ± 0.2 11.7 ± 0.4 11.1 ± 0.8
200 (24 h, n=8) 1.84 ± 0.2 1.63 ± 0.3 12.0 ± 0.4 11.6 ± 0.9
350 (24 h, n=7) 1.89 ± 0.2 1.39 ± 0.2* 12.7 ± 0.6 9.9 ± 1.3*
Data points are mean ± 1 SEM.
*P < .05, Student’s paired t test.
Antivascular and Antitumor Effects of DMXAA McPhail et al. 203
Neoplasia . Vol. 8, No. 3, 2006
decreased tumor blood flow may counterbalance each other.
At the highest dose of 350 mg/kg, the consistent decrease in
K trans and IAUGC with treatment suggests that the DCE-MRI
response is dominated by reduced tumor blood flow.
Figure 5. Summary of the response of the biomarkers (A) K trans and (B)
IAUGC to 200 mg/kg DMXAA 4 hours posttreatment (200 mg/kg*) (n = 7)
and to 0 mg/kg (n = 6), 100 mg/kg (n = 7), 200 mg/kg (n = 8), or 350 mg/kg
(n = 7) DMXAA 24 hours posttreatment (data points are ± 1 SEM; #P < .05,
Student’s t test).
Figure 6. Summary of the concentration of 5-HIAA in rat plasma samples
4 hours posttreatment with 200 mg/kg DMXAA (200 mg/kg*) (n = 4) and
24 hours posttreatment with 0 mg/kg (n = 4), 100 mg/kg (n = 5), 200 mg/kg
(n = 8), or 350 mg/kg (n = 4) DMXAA (data points are mean ± 1 SEM; #P <
.05, Student’s paired t test).
Figure 7. (A) A hematoxylin and eosin –stained section of aGH3 prolactinoma
24 hours posttreatment with vehicle. Grade 1, no necrosis. (B) A hematoxylin
and eosin–stained section of a GH3 prolactinoma tumor model 24 hours
posttreatment with 350mg/kg DMXAA. Grade 4, extensive necrosis (v = viable
tissue; n = necrosis).
Figure 8. Summary of necrosis grade in GH3 prolactinomas 4 hours
posttreatment with 200 mg/kg DMXAA (200 mg/kg*) (n = 5) and 24 hours
posttreatment with 0 mg/kg (n = 6), 100 mg/kg (n = 7), 200 mg/kg (n = 8), or
350 mg/kg (n = 7) DMXAA (data points are mean ± 1 SEM; #P < .05, Mann-
Whitney U test).
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Measurements of 5-HIAA support our conclusion from
the DCE-MRI results that DMXAA caused an increase in
vascular permeability, as there was a significant increase
in plasma 5-HIAA after treatment with 200 or 350 mg/kg
DMXAA. An increase in 5-HIAA concentration is indicative of
vascular damage and changes in vascular permeability be-
cause destruction of vascular endothelial cells leads to expo-
sure of the underlying basement membrane and induction of
platelet aggregation through the release of von Willebrand
factor. Subsequently, the aggregated platelets release sero-
tonin, which is itself a vasoactive compound with the poten-
tial to increase vascular permeability [5,20,29].
Taken together, the changes in DCE-MRI–derived bio-
markers and the 5-HIAA measurements of this study show
that DMXAA induced both an increase in vessel permeability
and a decrease in tumor blood flow in rat GH3 prolactinomas.
The DCE-MRI results only indicated a significant response
at the highest dose used in the study (350 mg/kg), whereas
the measurements of 5-HIAA indicated a significant re-
sponse after administration of 200 or 350mg/kgDMXAA.His-
tologic assessment of the tumors revealed that there were no
scores above grade 1 (no necrosis) for the control cohort,
there were more frequent scores above grade 1 for the 100-
and 200-mg/kg cohorts, and there was a significant induc-
tion of necrosis in the 350-mg/kg cohort.
The dual effects of DMXAA on tumor blood vessels may
also explain the absence of DCE-MRI dose response in
phase I clinical trials. Additionally, these findings emphasize
the continued need to identify alternative MRI biomarkers of
tumor response to DMXAA. For example, diffusion-weighted
MRI (which measures necrosis/water motility) and 19F MRI
oximetry or intrinsic susceptibility contrast MRI (which
derives R2* to provide an index of tissue oxygenation) could
be used. These methods have been exploited to assess the
effects of the VDAs combretastatin and ZD6126 [30–32].
To summarize, the results from this study suggest that
DMXAA caused an increase in vessel permeability, a reduc-
tion in rat tumor perfusion, and, consequently, the onset of
tumor necrosis due to starvation secondary to depleted
blood supply.
Acknowledgements
The authors thank Qi Ding for technical assistance and
performance of 5-HIAA HPLC analysis, and the staff at the
Biological Research Facility, St. George’s, University of Lon-
don, for supply and maintenance of the animals used.
References
[1] Siemann DW, Chaplin DJ, and Horsman MR (2004). Vascular-targeting
therapies for treatment of malignant disease. Cancer 100, 2491–2499.
[2] Tozer GM, Kanthou C, and Baguley BC (2005). Disrupting tumour blood
vessels. Nat Rev Cancer 5, 423–435.
[3] Denekamp J and Hobson B (1982). Endothelial-cell proliferation in ex-
perimental tumours. Br J Cancer 46, 711–720.
[4] LeachMO, Brindle KM, Evelhoch JL, Griffiths JR, HorsmanMR, Jackson
A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, et al. (2005). The
assessment of antiangiogenic and antivascular therapies in early-
stage clinical trials using magnetic resonance imaging: issues and rec-
ommendations. Br J Cancer 92, 1599–1610.
[5] Baguley BC, Zhuang Li, and Kestell P (1997). Increased plasma sero-
tonin following treatment with flavone-8-acetic acid, 5,6-dimethylxan-
thenone-4-acetic acid, vinblastine and colchicine: relation to vascular
effects. Oncol Res 9, 55–60.
[6] RustinG,BradleyC,Galbraith S, andStratfordM (2003). 5,6-Dimethylxan-
thenone-4-acetic acid (DMXAA), a novel antivascular agent: phase 1 phar-
macokinetic and pharmacodynamic study. Br J Cancer 88, 1160–1167.
[7] Zhou SF, Tingle MD, Kestell P, and Paxton JW (2002). Species differ-
ences in the metabolism of the antitumour agent 5,6-dimethylxanthe-
none-4-acetic acid in vitro: implications for prediction of metabolic
interactions in vivo. Xenobiotica 32, 87–107.
[8] McPhail LD, Chung YL, Basetti M, Clark S, Griffiths JR, Kelland LR, and
Robinson SP (2005). Tumour dose response to the vascular disrupting
agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic
resonance spectroscopy. Clin Cancer Res 11, 3705–3713.
[9] Freireich EJ, Gehan EA, Rall DP, Schmidt LH, and Skipper HE (1966).
Quantitative comparison of toxicity of anticancer agents in mouse, rat,
hamster, dog, monkey and man. Cancer Chemother Rep 50, 219–244.
[10] McIntyre DJO, Ludwig C, Pasan A, and Griffiths JR (2004). A method for
interleaved acquisition of a vascular input function for dynamic contrast-
enhanced MRI in experimental rat tumours. NMR Biomed 17, 132–143.
[11] Ludwig C, McIntyre DJO, and Griffiths JR (2003). Correction of errors in
estimatedGd-concentration fromT1-weighted gradient echo images due
to the spatial flip angle variation of surface coils. Magma 15, 228–229.
[12] Tofts PS and Kermode AG (1991). Measurement of the blood–brain
barrier permeability and leakage space using dynamic MR imaging. 1.
Fundamental concepts. Magn Reson Med 17, 357–367.
[13] Evelhoch JL (1991). Key factors in the acquisition of contrast kinetic
data for oncology. J Magn Reson Imaging 10, 254–259.
[14] Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes CK, and Baguley
BC (2001). Measurement of plasma 5-hydroxyindoleacetic acid as a
possible clinical surrogate marker for the action of antivascular agents.
Clin Chim Acta 314, 159–166.
[15] Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, and
Tozer GM (2002). Evaluation of the anti-vascular effects of combretas-
tatin in rodent tumours by dynamic contrast enhanced MRI. NMR
Biomed 15, 89–98.
[16] Robinson SP, McIntyre DJO, Checkley D, Tessier JJ, Howe FA, Griffiths
JR, Ashton SE, Ryan AJ, Blakey DC, and Waterton JC (2003). Tumour
dose response to the antivascular agent ZD6126 assessed by mag-
netic resonance imaging. Br J Cancer 88, 1592–1597.
[17] Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH,
Langmuir P, Wheeler C, Store A, Leadbetter J, et al. (2004). Magnetic
resonance imaging measurements of the response of murine and hu-
man tumors to the vascular-targeting agent ZD6126. Clin Cancer Res
10, 3650–3657.
[18] Galbraith SM, Rustin JS, Lodge MA, Taylor NJ, Stirling JJ, Jameson M,
Thompson P, Hough D, Gumbrell L, and Padhani AR (2002). Effects of
5,6-dimethylxanthenone-4-acetic acid on human tumour microcirculation
assessed by dynamic contrast-enhanced magnetic resonance imaging.
J Clin Oncol 20, 3826–3840.
[19] McKeage M, Fong P, Jeffery M, Ravic M, and Jameson MB (2005).
DART-A phase I safety and dose-finding study of the vascular targeting
agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in the treatment
of refractory tumours. Proc Am Soc Clin Oncol 3081, 212s.
Figure 9. Growth of GH3 prolactinomas posttreatment with either vehicle (E;
n = 4) or 350 mg/kg DMXAA (n; n = 4) (data points are mean ± 1 SEM;
*P < .02, **P < .01, Student’s t test).
Antivascular and Antitumor Effects of DMXAA McPhail et al. 205
Neoplasia . Vol. 8, No. 3, 2006
[20] Baguley BC (2003). Antivascular therapy of cancer: DMXAA. Lancet
Oncol 4, 141–148.
[21] Ferrero E, Villa A, Ferrero ME, Toninelli E, Bender JR, Pardi R, and
Zocchi MR (1996). Tumor necrosis factor alpha– induced vascular leak-
age involves PECAM1 phosphorylation. Cancer Res 56, 3211–3215.
[22] Hofmann S, Grasberger H, Jung P, Bidingmaier M, Vlotides J, Janssen
OE, and Landgraf R (2002). The tumour necrosis factor-alpha induced
vascular permeability is associated with a reduction of VE-cadherin ex-
pression. Eur J Med Res 30, 171–176.
[23] Lejeune FJ (2002). Clinical use of TNF revisited: improving penetration
of anti-cancer agents by increasing vascular permeability. J Clin Invest
110, 433–435.
[24] Nwariaku FE, Chang J, Zhu X, Liu Z, Duffy SL, Halaihel NH, Terada L,
and Turnage RH (2002). The role of p38 map kinase in tumor necrosis
factor – induced redistribution of vascular endothelial cadherin and in-
creased endothelial permeability. Shock 18, 82–85.
[25] Kerkar S, Williams M, Blocksom JM, Wilson RF, Tyburski JG, and
Steffes CP (2006). TNF-alpha and IL-1beta increase pericyte/endothe-
lial cell co-culture permeability. J Surg Res (in press).
[26] Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N,
Maeda M, and Urushizaki I (1988). Toxic effect of tumour necrosis
factor on tumour vasculature in mice. Cancer Res 48, 2179–2183.
[27] Kallinowski F, Schaefer C, Tyler G, and Vaupel P (1989). In vivo targets
of recombinant human tumour necrosis factor-alpha: blood flow,
oxygen consumption and growth of isotransplanted rat tumours. Br J
Cancer 60, 555–560.
[28] Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, and Baguley BC
(2002). Induction of endothelial cell apoptosis by the anti-vascular agent
5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86, 1937–1942.
[29] Feng D, Nagy JA, Hipp J, Dvorak HF, and Dvorak AM (1996). Vesiculo-
vacuolar organelles and the regulation of venule permeability to macro-
molecules by the vascular permeability factor, histamine, and serotonin.
J Exp Med 183, 1981–1986.
[30] Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H,
Hermans R, Verbeken EK, Boesch C, and Marchal G (2005). Effect of vas-
cular targeting agent in rat tumor model: dynamic contrast-enhanced
versus diffusion-weighted MR imaging. Radiology 237, 492–499.
[31] Zhao D, Jiang L, Hahn EW, and Mason RP (2005). Tumor physiologic
response to combretastatin A4 phosphate assessed by MRI. Int J
Radiat Oncol Biol Phys 62, 872–880.
[32] Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey
DC, Whittaker L, Ryan AJ, and Waterton JC (2005). Acute tumor re-
sponse to ZD6126 assessed by intrinsic susceptibility magnetic reso-
nance imaging. Neoplasia 7, 466–474.
206 Antivascular and Antitumor Effects of DMXAA McPhail et al.
Neoplasia . Vol. 8, No. 3, 2006
